Antagonist molecules in the treatment of angina

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 17, 2013, Pages 2323-2342

  Gupta, Ashish K ^a   Winchester, David ^a   Pepine, Carl J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angina pectoris; Cell therapy; Gene therapy; Novel drugs; Pharmacological management

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ARGININE; BEPRIDIL; CLOPIDOGREL; DIHYDROPYRIDINE; DILTIAZEM; ETOMOXIR; FASUDIL; FELODIPINE; IVABRADINE; MELDONIUM; MOLSIDOMINE; NEBIVOLOL; NICARDIPINE; NICORANDIL; NIFEDIPINE; NITRATE; OMAPATRILAT; OMECAMTIV MECARBIL; PERHEXILINE; RANOLAZINE; SILDENAFIL; TESTOSTERONE; TRIMETAZIDINE; UNINDEXED DRUG; VERAPAMIL;

ANGINA PECTORIS; ANGIOGENESIS; CELL THERAPY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY SPASM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HERBAL MEDICINE; HUMAN; LIFESTYLE MODIFICATION; MONOTHERAPY; NOCICEPTION; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; QUALITY OF LIFE; REVIEW; STABLE ANGINA PECTORIS;

ANGINA PECTORIS; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CARDIOVASCULAR AGENTS; CELL- AND TISSUE-BASED THERAPY; HUMANS; PHYTOTHERAPY;

EID: 84887985429     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.834329     Document Type: Review

References (147)

1. Opie LH. Angina pectoris: The evolution of concepts. J Cardiovasc Pharmacol Ther 2004;9.S3-9
2. World Health Organization. World health reports 2004: Changing history. Geneva: World Health Organization, 2004. Available from: Http://www.who. int/whr/2004/en/report04-en.pdf [Last accessed 6 August 2013]
3. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-e171
4. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: Overcoming impediments to prevention and control. JAMA 2004;291:2616-20
5. Kones R. Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag 2010;6:635-56
6. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. Physiol Rev 2008;88(3):1009-86
7. Westerhof N, Boer C, Lamberts RR, Sipkema P. Cross-Talk between cardiac muscle and coronary vasculature. Physiol Rev 2006;86(4):1263-308
8. Kones R. Recent advances in the management of chronic stable angina II: Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag 2010;6:749-74
9. Sharaf B, Pepine CJ, Kerensky RA. Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Womens Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). Am J Cardiol 2001;87:937-41
10. Fihn SD, Gardin JA, Berra K, et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/ STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary. A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126:3097-137
11. Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 Chronic angina focused update of the ACC/ AHA 2002 guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation 2007;116:2762-72
12. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: Executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-81
13. Smith SC, Allen J, Blair SN, et al. AHA/ ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72
14. Simoons ML, Windercker S. Chronic stable coronary artery disease: Drugs vs. revascularization. Eur Heart J 2010;31:530-41
15. Boden WE, ORourke RA, Teo KK, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356(15):1503-16
16. Maron D J, Boden WE, O'Rourke RA, et al. Intensive multifactorial intervention for stable coronary artery disease: Optimal medical therapy in the COURAGE trial. J Am Coll Cardiol 2010;55:1348-58
17. The BARI 2D Study Group. A randomized trial of therapy for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-15
18. Chaitman BR, Hardison RM, Adler D, et al. The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease. Impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009;120:2529-40
19. Chaitman BR, Hadid M, Laddu AA. Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes and stable ischemic coronary disease with special emphasis on the BARI 2D trial results. Curr Opin Cardiol 2010;25:597-602
20. Thomas S, Gokhale R, Boden WE, Devereaux PJ. A meta-Analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol 2013;29(4):472-82
21. Farkouh ME, Domanski M, Sleeper LA, et al. for FREEDOM trial investigators. Strategies for multivessel revascularization in patients with diabetes. New Eng J Med 2012;367:2375-84
22. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomized, clinical SYNTAX trial. Lancet 2013;381:629-38
23. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011;58:2432-6
24. Farkouh ME, Boden WE, Bittner V, et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol 2013;61(15):1607-15
25. Abrams J. Clinical practice. Chronic stable angina. N Engl J Med 2005;352:2524-33
26. Abrams J, Thadani U. Therapy of stable angina pectoris: The uncomplicated patient. Circulation 2005;112:e255-9
27. Kimchi A, Lee G, Amsterdam E, et al. Increased exercise tolerance after nitroglycerin oral spray: A new and effective therapeutic modality in angina pectoris. Circulation 1983;67:124-7
28. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988;260:2088-93
29. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996;17:76-81
30. Dargie HJ, Ford I, Fox KM. Total Ischemic Burden European Trial (TIBET). Effects of ischemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996;17:104-12
31. Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 1996;17:96-103
32. Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-Term treatment in patients with chronic stable angina: A double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992;19:409-17
33. Glasser SP, Gana TJ, Pascual LG, Albert KS. Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris. Am Heart J 2005;149:e1-9
34. Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999;83:507-14
35. Kohli RS, Rodrigues EA, Hughes LO, et al. Sustained release verapamil, a once daily preparation: Objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina. J Am Coll Cardiol 1987;9:615-21
36. Pepine CJ, Handberg E, Cooper-DeHoff RM, et al. for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003;290:2805-16
37. Bangalore S, Steg G, Deedwania P, et al. b-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308(13):1340-9
38. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-Term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82
39. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 2004;291:309-16
40. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566-75
41. Vadanis DS, Wenger NK. Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Manag 2010;6:517-30
42. The IONA Study Group. Trial to show the impact of nicorandil in angina (IONA): Design, methodology, and management. Heart 2001;85(6):e9
43. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: The Impact of Nicorandil in Angina (IONA) randomized trial. Lancet 2002;359:1269-75
44. Horinaka S, Yabe A, Yagi H, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010;74(3):503-9
45. Hollingshead LM, Faulds D, Fitton A. B. A review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs 1992;44:835-57
46. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res 2010;106:434-46
47. Baruscotti M, Barbuti A, Bucchi A. The cardiac pacemaker current. J Mol Cell Cardiol 2010;48:55-64
48. Savelieva I, Camm AJ. If inhibition with ivabradine: Electrophysiological effects and safety. Drug Saf 2008;31:95-107
49. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin 2005;21(7):1115-22
50. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-36
51. Tardif JC, Ponikowski P, Kahan T. Efficacy of the i(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: A 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540-8
52. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and anti-ischemic effects of ivabradine, an I(f) inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-23
53. Chaitman BR, Sano J. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease. Clin Cardiol 2007;30(Suppl 1):I25-30
54. Ciapponi A, Pizzarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005(4):CD003614
55. Ribeiro LW, Ribeiro JP, Stein R, et al. Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: A randomized crossover trial. Am Heart J 2007;154:78.e1-7
56. MacInnes A, Fairman DA, Binding P, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003;93:e26-32
57. Marazzi G, Wajngarten M, Vitale C, et al. Effect of fatty acid inhibition on silent and symptomatic myocardial ischemic in diabetic patients with coronary artery disease. Int J Cardiol 2007;120:79-84
58. Pornin M, Harpey C, Allal J, et al. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: A placebo-controlled study. Clin Trials Metaanal 1994;29(1):49-56
59. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86(5):580-8
60. Casino PR, Kilcoyne CM, Quyyumi AA, et al. Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol 1994;23(4):844-50
61. Campisi R, Czernin J, Schoder H, et al. L-Arginine normalizes coronary vasomotion in long-Term smokers. Circulation 1999;99(4):491-7
62. Chauhan A, More RS, Mullins PA, et al. Aging-Associated endothelial dysfunction in humans is reversed by l-Arginine. J Am Coll Cardiol 1996;28(7):1796-800
63. Tentolouris C, Tousoulis D, Toutouzas P, Davies G. Effects of acute L-Arginine administration in coronary atherosclerosis. Circulation 1999;99(12):1648-9
64. Tentolouris C, Tousoulis D, Davies GJ, et al. Serum cholesterol level, cigarette smoking, and vasomotor responses to L-Arginine in narrowed epicardial coronary arteries. Am J Cardiol 2000;85(4):500-3
65. Egashira K, Hirooka Y, Kuga T, et al. Effects of L-Arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996;94(2):130-4
66. Walker HA, McGing E, Fisher I, et al. Endothelium-dependent vasodilation is independent of the plasma L-Arginine/ ADMA ratio in men with stable angina: Lack of effect of oral l-Arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001;38(2):499-505
67. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral l-Arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997;80(3):331-3
68. Abozguia K, Shivu GN, Ahmed I, et al. The heart metabolism: Pathophysiological aspects in ischemia and heart failure. Curr Pharm Des 2009;15:827-35
69. Roberts RK, Cohn D, Petroff V, Seneviratne B. Liver disease induced by perhexiline maleate. Med J Aust 1981;2:553-4
70. Bouche P, Bousser MG, Peytour MA, Cathala H. Perhexiline maleate and peripheral neuropathy. Neurology 1979;29:739-43
71. Morgan MY, Reshef R, Shah RR, et al. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984;25:1057-64
72. Phan TT, Shivu GN, Choudhary A, et al. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: Old drug, new hope. Eur J Heart Fail 2009;11(9):881-6
73. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol 2002;18:439-42
74. Lopaschuk G, Wall S, Olley P, Davies N. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988;63(6):1036-43
75. Reaven GM, Chang H, Hoffman BB. Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Diabetes 1988;37(1):28-32
76. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur Heart J 2004;25(8):634-41
77. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000;99:27-35
78. Holubarsch CJ, Rohrbach M, Karrasch M, et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007;113:205-12
79. Trippodo NC, Fox M, Natarajan V, et al. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. Pharmacol Exp Ther 1993;267(1):108-16
80. Chaitman BR, Ivleva AY, Ujda M, et al. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. Am J Cardiol 2005;95(11):1283-9
81. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011;301:H287-9
82. Vicari RM, Chaitman B, Keefe D, et al. Fasudil Study Group. Efficacy and safety of fasudil in patients with stable angina: A double blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005;46(10):1803-11
83. Kwang-Seok O, Oh BK, Park CH, et al. Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl) amino-4-methoxy-6- piperazino triazine (DW1865). Eur J Pharmacol 2013;702:218-26
84. Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomized, placebo controlled crossover trial. Lancet 2010;375:2161-7
85. Chou TM, Sudhir K, Hutchison SJ, et al. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation 1996;94(10):2614-19
86. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: A review. Atherosclerosis 1996;125:1-13
87. English KM, Mandour O, Steed RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000;21:890-4
88. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double blind, placebo-controlled study. Circulation 2000;102(16):1906-11
89. Jaffe MD. Effect of testosterone cypionate on post-exercise ST segment depression. Br Heart J 1977;39:1217-22
90. Wu SZ, Weng XZ. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chinese Med J 1993;106:415-18
91. Webb CM, Adamson DL, Dezeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999;83:437-9
92. Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circ 1999;99:1666-70
93. Webb CM, McNeil JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999;100:1690-6
94. Magness RR, Rosenfeld CR. Local and systemic estradiol-17 beta: Effects on uterine and systemic vasodilation. Am J Physiol Endocrinol Metab 1989;256(4):E536-42
95. Sanderson EJ, Sanderson J, Haines CJ, et al. Anti-ischemic action of estrogen-progestogen continuous combined hormone replacement therapy in postmenopausal women with established angina pectoris: A randomized, placebo-controlled, double-blind, parallel-group trial. J Cardiovasc Pharmacol 2001;38(3):372-83
96. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33
97. Nitz RE, Fiedler VB. Molsidomine: Alternative approaches to treat myocardial ischemia. Pharmacotherapy 1987;7:28-37
98. Van Hove C, Carreer-Bruhwyler F, Géczy J, et al. Long-Term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina. Atherosclerosis 2005;180:399-405
99. Messin R, Opolski G, Fenyvesi T, et al. Efficacy and safety of molsidomine once-A-day in patients with stable angina pectoris. Int J Cardiol 2005;98:79-89
100. Sesti C, Simkhovich BZ, Kalvinsh I, Kloner R. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J Cardiovasc Pharm 2006;47(3):493-9
101. Dzerve V, Matisone D, Pozdnyakov Y, Oganov R. Mildronate improves the exercise tolerance in patients with stable angina: Results of a long term clinical trial. Sem Cardiovasc Med 2010;16(3):1-8
102. Dzerve V; MILSS I Study Group. A dose dependent improvement in exercise tolerance in patients with stable angina treated with Midronate: A clinical trial MILSS I. Medicina (B Aires) 2011;47(10):544-51
103. Schwartz BG, Jackson G, Stecher VJ, et al. Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. Am J Med 2013;126:192-9
104. Meyer BJ, Amann FW. Additional antianginal efficacy of amiodarone in patients with limiting angina pectoris. Am Heart J 1993;125:996-1001
105. Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: A first-in-man study. Lancet 2011;378:667-75
106. Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 2010;3:522-7
107. Cleland JGF, Teerlink JR, Senior R, et al. The effects of cardiac myosin activator, omecamtiv mecarbil on cardiac function in systolic heart failure: A double blind, placebo controlled, crossover, dose-ranging phase 2 trial. Lancet 2011;378:676-83
108. Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2003;2:1291-7
109. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95
110. Henry TD, Abraham JA. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis. Curr Interv Cardiol Rep 2000;2:228-41
111. Udelson JE, Dilsizian V, Laham RJ, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-10
112. Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect. Circulation 2000;101:118-21
113. Henry TD, Rocha-Singh K, Isner JM, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 2001;142:872-80
114. Attanasio S, Schaer G. Therapeutic angiogenesis for management of refractory angina: Current concepts. Cardiovasc Ther 2011;29:e1-e11
115. Mitsos S, Katsanos K, Koletsis E, et al. Therapeutic angiogenesis for myocardial ischemia revisited: Basic biologic concepts and focus on latest clinical trials. Angiogenesis 2012;15:1-22
116. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodeling. Cardiovasc Res 2009;81:519-27
117. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-21
118. Schachinger V, Erbs S, Elsasser A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: Final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006;27:2775-83
119. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008;451:937-42
120. Templin C, Luscher TF, Landmesser U. Cell-based cardiovascular repair and regeneration in acute myocardial infarction and chronic ischemic cardiomyopathy: Current status and future developments. Int J Dev Biol 2011;55:407-17
121. Sequeira C, Park K, Pepine CJ, Cogle C. Stem and progenitor cell therapies for cardiovascular disease. J Cell Sci Ther 2011;S1:1-9
122. Mozid AM, Arnous S, Sammut EC, Mathur A. Stem cell therapy for heart disease. Br Med Bull 2011;98:143-59
123. Wu KH, Mo XM, Han ZC, Zhou B. Stem cell engraftment and survival in the ischemic heart. Ann Thorac Surg 2011;92:1917-25
124. Strauer BE, Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart from the methodological origin to clinical practice. J Am Coll Cardiol 2011;58:1095-104
125. van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: A randomized controlled trial. JAMA 2009;301:1997-2004
126. Tse HF, Thambar S, Kwong YL, et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECTCAD trial). Eur Heart J 2007;28:2998-3005
127. Losardo DW, Henry TD, Davidson C, et al. ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011;109:428-36
128. Kovacic J, Macdonald P, Feneley M, et al. Safety and efficacy of consecutive cycles of granulocyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: The G-CSF in Angina patients with IHD to stimulate Neovascularization (GAIN 1) trial. Am Heart J 2008;156:954-63
129. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204-19
130. Ceradini DJ, Kulkarni AR, Callagan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64
131. O'Brien KA, Vitetta L. The potential role of herbal medicines in the treatment of chronic stable angina pectoris: A review of key herbs, and as illustration, exploration of the Chinese herbal medicine approach. Botanics: Targets and Therapy 2013;3:1-17
132. Lievre M, Cucherat M. Aspirin in the secondary prevention of cardiovascular disease: An update of the APTC meta-Analysis. Fundam Clin Pharmacol 2010;24:385-91
133. Bhatt D, Fox AA, Fox MB, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Eng J Med 2006;354:1706-14
134. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170,000 participants in 26 randomized trials. Lancet 2010;376:1670-81
135. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
136. Bakris GL, Fonesca V, Katholi RE, et al. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA 2004;292:2227-36
137. Weiss R, Ferry D, Pickering E, et al. Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol Angina Study Group. Am J Cardiol 1998;82:927-31
138. Van Der Does R, Hauf-Zachariou U, Pfarr E, et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am J Cardiol 1999;83:643-9
139. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, et al. Carvedilol versus verapamil in chronic stable angina: A multicentre trial. Eur J Clin Pharmacol 1997;52:95-100
140. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-Analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62
141. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-Analysis. Lancet 2007;269:201-7
142. Kobusiak-Prokopowicz M, Jolda-Mydlowska B, Zubkiewicz A, et al. Impact of nebivolol on levels of serum nitric oxide, plasma von Willebrand factor and exercise stress testing parameters in hypertensive and ischemic heart disease patients. Cardiol J 2008;15:162-8
143. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Eng J Med 1998;338:520-31
144. Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in Angina Combination Therapy-The TACT study: Trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebocontrolled, multicenter study. Am J Ther 2005;12:35-42
145. Ghofrani HA, Gahe N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Eng J Med 2013;369:330-40
146. Ghofrani HA, Gahe N, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Eng J Med 2013;369:319-29
147. Staples M. Microchips and controlled-release drug reservoirs. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010;2(4):400-17